Proxalutamide for the treatment of COVID‐19 rebound following Paxlovid treatment: Report of four cases and review of the literature

Abstract

AbstractBackgroundThe pandemic the coronavirus disease 2019 (COVID‐19) has created a global health crisis. Although Paxlovid is recommended for the early‐stage treatment of mild‐to‐moderate COVID‐19 in patients at increased risk of progression to severe COVID‐19, more and more cases are reported a COVID‐19 rebound after Paxlovid treatment. Currently, information on the additional treatment for COVID‐19 rebound following Paxlovid treatment is limited.Case ReportHere, we present four cases with COVID‐19 who were mild on admission. All cases experienced a COVID‐19 rebound and progressed to severe COVID‐19, following treatment with Paxlovid (300 mg of nirmatrelvir with 100 mg ritonavir, twice daily for 5 days). After being treated with proxalutamide (300 mg/day), all cases finally turned real‐time reverse transcription polymerase chain reaction (RT‐PCR) negative.ConclusionOur cases suggested that proxalutamide might be an effective remedial treatment option for patients experiencing a COVID‐19 rebound after Paxlovid treatment.